Could the ketogenic diet offer hope in management of neurological diseases?

Abstract

The ketogenic diet (KD) is a nutritional model that includes high fat, moderate protein, and low carbohydrate (less than 50 g). The “KD ratio” is used to determine the amount of macronutrients in the diet. In classical KD with the ratio of 3:1 or 4:1, 85–90% of the energy is provided from dietary fat. In addition to classical KD, the modified Atkins diet, low glycemic index therapy, and medium-chain triglyceride diet have also been used, and in some studies, ketosis has been achieved with exogenous ketone supplements. KD has long been recognized as a successful dietary approach in the treatment of refractory epilepsy. It is known that KD may also be effective in other neurological diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and migraine through various mechanisms such as providing an alternative energy source for neurons, reducing inflammation and oxidative stress, stimulating neurotransmitter synthesis and regulation of microbiota, etc. However, existing evidence is insufficient to make definitive conclusions about the effect of the KD on neurological diseases other than epilepsy due to the short intervention time, the small sample size, and the heterogeneity in the study methods. Considering factors such as genetics, endocrine differences, timing, and diet composition, it is important to apply and follow precision nutrition programs to increase the benefits of KD and reduce its side effects. In this review, the mechanisms of the KD on neurological diseases, recent evidence on the use of the KD in neurological diseases other than epilepsy, the limitations and difficulties in the literature on the KD, and the contraindications of the KD were discussed in detail.

Keywords

Ketogenic diet / neurological disease / Alzheimer’s / Parkinson’s / multiple sclerosis / migraine

References

[1] Wheless JW. History of the ketogenic diet. Epilepsia. 2008; 49: 3-5.

[2] Batch JT, Lamsal SP, Adkins M, Sultan S, Ramirez MN. Advantages and Disadvantages of the Ketogenic Diet: A Review Article. Cureus. 2020; 12: e9639.

[3] Türkiye Çocuk Nörolojisi Derneği. Dirençli Epilepsili Çocuk Hastalarda Ketojenik Diyet Tedavisi Klinik Rehberi. İstanbul: Berkman Padar Yayın Grubu; 2021.

[4] Roehl K, Sewak SL. Practice Paper of the Academy of Nutrition and Dietetics: Classic and Modified Ketogenic Diets for Treatment of Epilepsy. J Acad Nutr Diet. 2017; 117: 1279-92.

[5] Miranda MJ, Turner Z, Magrath G. Alternative diets to the classical ketogenic diet——can we be more liberal? Epilepsy Res. 2012; 100: 278-85.

[6] Neal E. “Alternative” ketogenic diets. In: Masino S, editor. Ketogenic Diet and Metabolic Therapies: Expanded Roles in Health and Disease. New York: Oxford University Press; 2022. pp. 5-15.

[7] Kossoff EH. The Modified Atkins Diet for Epilepsy: Two Decades of an “Alternative” Ketogenic Diet Therapy. Pediatr Neurol. 2023; 147: 82—7.

[8] Harvey CJDC, Schofield GM, Williden M. The use of nutritional supplements to induce ketosis and reduce symptoms associated with keto—induction: a narrative review. PeerJ. 2018; 6: e4488.

[9] Falkenhain K, Islam H, Little JP. Exogenous ketone supplementation: an emerging tool for physiologists with potential as a metabolic therapy. Exp Physiol. 2023; 108: 177-87.

[10] Zhu H, Bi D, Zhang Y, Kong C, Du J, Wu X, et al. Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. Signal Transduct Target Ther. 2022; 7: 11.

[11] Wang Y, Zhang J, Zhang Y, Yao J. Bibliometric analysis of global research profile on ketogenic diet therapies in neurological diseases: Beneficial diet therapies deserve more attention. Front Endocrinol (Lausanne). 2023; 13: 1066785.

[12] Nanda M, Pradhan G, Singh V, Barve K. Ketogenic diets: Answer to life—threatening neurological diseases. Food and Humanity. 2024; 3: 100364.

[13] Avgerinos KI, Egan JM, Mattson MP, Kapogiannis D. Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer’s disease. A systematic review and meta—analysis of human studies. Ageing Res Rev. 2020; 58: 101001.

[14] Grammatikopoulou MG, Goulis DG, Gkiouras K, Theodoridis X, Gkouskou KK, Evangeliou A, et al. To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. Adv Nutr. 2020; 11: 1583-602.

[15] Hersant H, Grossberg G. The Ketogenic Diet and Alzheimer’s Disease. J Nutr Health Aging. 2022; 26: 606—14.

[16] Lilamand M, Porte B, Cognat E, Hugon J, Mouton—Liger F, Paquet C. Are ketogenic diets promising for Alzheimer’s disease? A translational review. Alzheimers Res Ther. 2020; 12: 42.

[17] Pavón S, Lázaro E, Martínez O, Amayra I, López—Paz JF, Caballero P, et al. Ketogenic diet and cognition in neurological diseases: a systematic review. Nutr Rev. 2021; 79: 802-13.

[18] Bohnen JLB, Albin RL, Bohnen NI. Ketogenic interventions in mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease: A systematic review and critical appraisal. Front Neurol. 2023; 14: 1123290.

[19] Choi A, Hallett M, Ehrlich D. Nutritional Ketosis in Parkinson’s Disease — a Review of Remaining Questions and Insights. Neurotherapeutics. 2021; 18: 1637-49.

[20] Price S, Ruppar TM. Ketogenic therapies in Parkinson’s disease, Alzheimer’s disease, and mild cognitive impairment: An integrative review. Appl Nurs Res. 2023; 74: 151745.

[21] Brenton JN, Lehner—Gulotta D, Woolbright E, Banwell B, Bergqvist AGC, Chen S, et al. Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. J Neurol Neurosurg Psychiatry. 2022; 93: 637-44.

[22] Brockhoff JD, Bereswill S, Heimesaat MM. The impact of ketogenic diet on the onset and progression of multiple sclerosis. Eur J Microbiol Immunol (Bp). 2023; 13: 29-36.

[23] Bongiovanni D, Benedetto C, Corvisieri S, Favero CD, Orlandi F, Allais G, et al. Effectiveness of ketogenic diet in treatment of patients with refractory chronic migraine. Neurol Sci. 2021; 42: 3865—70.

[24] Caminha MC, Moreira AB, Matheus FC, Rieger DK, Moreira JD, Dalmarco EM, et al. Efficacy and tolerability of the ketogenic diet and its variations for preventing migraine in adolescents and adults: a systematic review. Nutr Rev. 2022; 80: 1634—47.

[25] Haslam RL, Bezzina A, Herbert J, Spratt N, Rollo ME, Collins CE. Can Ketogenic Diet Therapy Improve Migraine Frequency, Severity and Duration? Healthcare (Basel). 2021; 9: 1105.

[26] Neri LdCL, Ferraris C, Catalano G, Guglielmetti M, Pasca L, Pezzotti E, et al. Ketosis and migraine: a systematic review of the literature and meta—analysis. Front Nutr. 2023; 10: 1204700.

[27] Pietrzak D, Kasperek K, Rękawek P, Piątkowska—Chmiel I. The Therapeutic Role of Ketogenic Diet in Neurological Disorders. Nutrients. 2022; 14: 1952.

[28] Dyńka D, Kowalcze K, Paziewska A. The Role of Ketogenic Diet in the Treatment of Neurological Diseases. Nutrients. 2022; 14: 5003.

[29] Mazandarani M, Lashkarbolouk N, Ejtahed H, Qorbani M. Does the ketogenic diet improve neurological disorders by influencing gut microbiota? A systematic review. Nutr J. 2023; 22: 61.

[30] Lim J, Letchumanan V, Tan LT, Hong K, Wong S, Mutalib NA, et al. Ketogenic Diet: A Dietary Intervention via Gut Microbiome Modulation for the Treatment of Neurological and Nutritional Disorders (a Narrative Review). Nutrients. 2022; 14: 3566.

[31] Santangelo A, Corsello A, Spolidoro GCI, Trovato CM, Agostoni C, Orsini A, et al. The Influence of Ketogenic Diet on Gut Microbiota: Potential Benefits, Risks and Indications. Nutrients. 2023; 15: 3680.

[32] Rew L, Harris MD, Goldie J. The ketogenic diet: its impact on human gut microbiota and potential consequent health outcomes: a systematic literature review. Gastroenterol Hepatol Bed Bench. 2022; 15: 326-42.

[33] Paoli A, Mancin L, Bianco A, Thomas E, Mota JF, Piccini F. Ketogenic Diet and Microbiota: Friends or Enemies? Genes (Basel). 2019; 10: 534.

[34] Jiang Z, Yin X, Wang M, Chen T, Wang Y, Gao Z, et al. Effects of Ketogenic Diet on Neuroinflammation in Neurodegenerative Diseases. Aging Dis. 2022; 13: 1146—65.

[35] Agnihotri A, Aruoma OI. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals. J Am Coll Nutr. 2020; 39: 16-27.

[36] Al—Kuraishy HM, Jabir MS, Albuhadily AK, Al—Gareeb AI, Jawad SF, Swelum AA, et al. Role of ketogenic diet in neurodegenerative diseases focusing on Alzheimer diseases: The guardian angle. Ageing Res Rev. 2024; 95: 102233.

[37] Fote GM, Geller N, Reyes—Ortiz A, Thompson L, Steffan J, Grill JD. A scoping review of dietary factors conferring risk or protection for cognitive decline in APOE ε4 carriers. J Nutr Health Aging. 2021; 25: 1167—78.

[38] Buckinx F, Aubertin—Leheudre M. Nutrition to Prevent or Treat Cognitive Impairment in Older Adults: A GRADE Recommendation. J Prev Alzheimers Dis. 2021; 8: 110-16.

[39] Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017; 3: 17013.

[40] Tosefsky KN, Zhu J, Wang YN, Lam JST, Cammalleri A, Appel—Cresswell S. The Role of Diet in Parkinson’s Disease. J Parkinsons Dis. 2024; 14: S21-34.

[41] Bisaglia M. Mediterranean Diet and Parkinson’s Disease. Int J Mol Sci. 2023; 24: 42.

[42] Knight E, Geetha T, Burnett D, Babu JR. The Role of Diet and Dietary Patterns in Parkinson’s Disease. Nutrients. 2022; 14: 4472.

[43] Grammatikopoulou MG, Tousinas G, Balodimou C, Anastasilakis DA, Gkiouras K, Dardiotis E, et al. Ketogenic therapy for Parkinson’s disease: A systematic review and synthesis without meta—analysis of animal and human trials. Maturitas. 2022; 163: 46-61.

[44] Ward M, Goldman MD. Epidemiology and Pathophysiology of Multiple Sclerosis. Continuum (Minneap Minn). 2022; 28: 988-1005.

[45] Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell—Based Therapy. Cell J. 2017; 19: 1-10.

[46] Tarlinton RE, Khaibullin T, Granatov E, Martynova E, Rizvanov A, Khaiboullina S. The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis. Int J Mol Sci. 2019; 20: 303.

[47] Stoiloudis P, Kesidou E, Bakirtzis C, Sintila S, Konstantinidou N, Boziki M, et al. The Role of Diet and Interventions on Multiple Sclerosis: A Review. Nutrients. 2022; 14: 1150.

[48] Majo DD, Cacciabaudo F, Accardi G, Gambino G, Giglia G, Ferraro G, et al. Ketogenic and Modified Mediterranean Diet as a Tool to Counteract Neuroinflammation in Multiple Sclerosis: Nutritional Suggestions. Nutrients. 2022; 14: 2384.

[49] Lin W, Lin S, Liao P, Suresh D, Hsu T, Wang P. Role of Ketogenic Diets in Multiple Sclerosis and Related Animal Models: An Updated Review. Adv Nutr. 2022; 13: 2002-14.

[50] Atabilen B, Akdevelioğlu Y. Effects of different dietary interventions in multiple sclerosis: a systematic review of evidence from 2018 to 2022. Nutr Neurosci. 2023; 26: 1279-91.

[51] Wetmore E, Lehner—Gulotta D, Florenzo B, Banwell B, Bergqvist AGC, Coleman R, et al. Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post—trial diet adherence & outcomes. Clin Nutr. 2023; 42: 1427—35.

[52] Eigenbrodt AK, Ashina H, Khan S, Diener H, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021; 17: 501—14.

[53] Lorenzo CD, Ballerini G, Barbanti P, Bernardini A, D’Arrigo G, Egeo G, et al. Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations. Nutrients. 2021; 13: 2307.

[54] Fila M, Chojnacki J, Pawlowska E, Sobczuk P, Chojnacki C, Blasiak J. The Ketogenic Diet in the Prevention of Migraines in the Elderly. Nutrients. 2023; 15: 4998.

[55] Post A, Garcia E, Berg EHvd, Flores—Guerrero JL, Gruppen EG, Groothof D, et al. Nonalcoholic fatty liver disease, circulating ketone bodies and all—cause mortality in a general population—based cohort. Eur J Clin Invest. 2021; 51: e13627.

[56] Niezen S, Connelly MA, Hirsch C, Kizer JR, Benitez ME, Minchenberg S, et al. Elevated Plasma Levels of Ketone Bodies Are Associated With All—Cause Mortality and Incidence of Heart Failure in Older Adults: The CHS. J Am Heart Assoc. 2023; 12: e029960.

[57] Alharbi A, Al—Sowayan NS. The effect of ketogenic—diet on health. Food and Nutrition Sciences. 2020; 11: 301-13.

[58] Mellenia K, Santoso AH. Ketogenic Keys to Body Composition: Nutritional Insights and Comparative Dietary Effects. BioSci Med J Biomed Transl Res. 2024; 8: 4497-505.

[59] Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low—fat versus ketogenic diet in Parkinson’s disease: A pilot randomized controlled trial. Mov Disord. 2018; 33: 1306-14.

[60] Crosby L, Davis B, Joshi S, Jardine M, Paul J, Neola M, et al. Ketogenic Diets and Chronic Disease: Weighing the Benefits Against the Risks. Front Nutr. 2021; 8: 702802.

[61] Goldberg IJ, Ibrahim N, Bredefeld C, Foo S, Lim V, Gutman D, et al. Ketogenic diets, not for everyone. J Clin Lipidol. 2021; 15: 61-7.

[62] Wei S, Schell JR, Chocron ES, Varmazyad M, Xu G, Chen WH, et al. Ketogenic diet induces p53—dependent cellular senescence in multiple organs. Sci Adv. 2024; 10: eado1463.

[63] Watanabe M, Tuccinardi D, Ernesti I, Basciani S, Mariani S, Genco A, et al. Scientific evidence underlying contraindications to the ketogenic diet: An update. Obes Rev. 2020; 21: e13053.

[64] Ferraris C, Guglielmetti M, Neri LdCL, Allehdan S, Albasara JMM, Alawadhi HHF, et al. A Review of Ketogenic Dietary Therapies for Epilepsy and Neurological Diseases: A Proposal to Implement an Adapted Model to Include Healthy Mediterranean Products. Foods. 2023; 12: 1743.

[65] Liu Y, Fan L, Yang H, Wang D, Liu R, Shan T, et al. Ketogenic therapy towards precision medicine for brain diseases. Front Nutr. 2024; 11: 1266690.